"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","treatment_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","data_processing.1","platform_id","contact_name","contact_email","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","disease:ch1"
"GSM1494634","Control N1","GSM1494634","Public on Sep 03 2014","Sep 02 2014","Sep 03 2014","RNA","1","Control","Homo sapiens","disease: Control","Blood samples from 5 KD patients and 5 KD patients after IVIG therapy were randomly selected according to the American Heart Association and the Japanese Ministry of Health and Welfare criteria.Blood samples from 5 healthy children were used as control group. All the diagnoses of these patients were confirmed by more than two pediatric cardiologists and other diseases were excluded. Serum were separated by centrifugation at 1,000 脳g for 10 min. Serum aliquots were collected and stored at -80掳C. The serum obtained was further processed for exosome isolation.","total RNA","We isolated exosomes of sera from all participants by using ExoQuick precipitation following manufacturer's instructions, Total RNA extracted using Trizol following manufacturer's instructions","Cy3","100 ng of total RNA(including miRNA) were dephosphorylated and denaturated,then ligated with Cyanine 3-pCp at 16℃ for 2 hours using T4 RNA Ligase.","9606","Oligoarray control targets and hybridization buffer (Agilent miRNA Spike- In kit and miRNA Hybridization Kit) were added, and samples were applied to microarrays enclosed in Agilent SureHyb-enabled hybridization chambers. After hybridization, slides were washed sequential","Slides were scanned by Agilent Microarray Scanner(Cat#G2565BA锛孉gilent technologies, Santa Clara, CA, US)","human miRNA expression after control human serum samples","Images were quantified using Agilent Feature Extraction Software (version 10.7.1.1).","Raw data were normalized by Quantile algorithm, Gene Spring Software 11.0(Agilent technologies, Santa Clara, CA, US).","GPL16730","Hong-Ling,,Jia","15918731131@139.com","Jinan University","Huangpu Road","Guangzhou","Guangdong","510632","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1494nnn/GSM1494634/suppl/GSM1494634_N1_253965910016_S01_miRNA_107_Sep09_105_1_4.txt.gz","0","Control"
"GSM1494635","Kawasaki disease","GSM1494635","Public on Sep 03 2014","Sep 02 2014","Sep 03 2014","RNA","1","Kawasaki disease","Homo sapiens","disease: Kawasaki disease","Blood samples from 5 KD patients and 5 KD patients after IVIG therapy were randomly selected according to the American Heart Association and the Japanese Ministry of Health and Welfare criteria.Blood samples from 5 healthy children were used as control group. All the diagnoses of these patients were confirmed by more than two pediatric cardiologists and other diseases were excluded. Serum were separated by centrifugation at 1,000 脳g for 10 min. Serum aliquots were collected and stored at -80掳C. The serum obtained was further processed for exosome isolation.","total RNA","We isolated exosomes of sera from all participants by using ExoQuick precipitation following manufacturer's instructions, Total RNA extracted using Trizol following manufacturer's instructions","Cy3","100 ng of total RNA(including miRNA) were dephosphorylated and denaturated,then ligated with Cyanine 3-pCp at 16℃ for 2 hours using T4 RNA Ligase.","9606","Oligoarray control targets and hybridization buffer (Agilent miRNA Spike- In kit and miRNA Hybridization Kit) were added, and samples were applied to microarrays enclosed in Agilent SureHyb-enabled hybridization chambers. After hybridization, slides were washed sequential","Slides were scanned by Agilent Microarray Scanner(Cat#G2565BA锛孉gilent technologies, Santa Clara, CA, US)","human miRNA expression after Kawasaki disease human serum samples","Images were quantified using Agilent Feature Extraction Software (version 10.7.1.1).","Raw data were normalized by Quantile algorithm, Gene Spring Software 11.0(Agilent technologies, Santa Clara, CA, US).","GPL16730","Hong-Ling,,Jia","15918731131@139.com","Jinan University","Huangpu Road","Guangzhou","Guangdong","510632","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1494nnn/GSM1494635/suppl/GSM1494635_B_253965910016_S01_miRNA_107_Sep09_105_2_2.txt.gz","0","Kawasaki disease"
"GSM1494636","Kawasaki disease after Intravenous immunoglobulin (IVIG) therapy","GSM1494636","Public on Sep 03 2014","Sep 02 2014","Sep 03 2014","RNA","1","Kawasaki disease after Intravenous immunoglobulin (IVIG) therapy","Homo sapiens","disease: Kawasaki disease after Intravenous immunoglobulin (IVIG) therapy","Blood samples from 5 KD patients and 5 KD patients after IVIG therapy were randomly selected according to the American Heart Association and the Japanese Ministry of Health and Welfare criteria.Blood samples from 5 healthy children were used as control group. All the diagnoses of these patients were confirmed by more than two pediatric cardiologists and other diseases were excluded. Serum were separated by centrifugation at 1,000 脳g for 10 min. Serum aliquots were collected and stored at -80掳C. The serum obtained was further processed for exosome isolation.","total RNA","We isolated exosomes of sera from all participants by using ExoQuick precipitation following manufacturer's instructions, Total RNA extracted using Trizol following manufacturer's instructions","Cy3","100 ng of total RNA(including miRNA) were dephosphorylated and denaturated,then ligated with Cyanine 3-pCp at 16℃ for 2 hours using T4 RNA Ligase.","9606","Oligoarray control targets and hybridization buffer (Agilent miRNA Spike- In kit and miRNA Hybridization Kit) were added, and samples were applied to microarrays enclosed in Agilent SureHyb-enabled hybridization chambers. After hybridization, slides were washed sequential","Slides were scanned by Agilent Microarray Scanner(Cat#G2565BA锛孉gilent technologies, Santa Clara, CA, US)","human miRNA expression after Kawasaki disease after Intravenous immunoglobulin (IVIG) therapy human serum samples","Images were quantified using Agilent Feature Extraction Software (version 10.7.1.1).","Raw data were normalized by Quantile algorithm, Gene Spring Software 11.0(Agilent technologies, Santa Clara, CA, US).","GPL16730","Hong-Ling,,Jia","15918731131@139.com","Jinan University","Huangpu Road","Guangzhou","Guangdong","510632","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1494nnn/GSM1494636/suppl/GSM1494636_A_253965910016_S01_miRNA_107_Sep09_105_2_1.txt.gz","0","Kawasaki disease after Intravenous immunoglobulin (IVIG) therapy"
